Endpoints For Therapeutic Trials In ILD

Endpoints For Therapeutic Trials In ILD

Regular price
Conference Bundle: FREE
Member: $39.20 Non-Member: $49.00
Sale price
Conference Assistant: FREE
Member: $39.20
Regular price
Non-Member: $49.00
Sold out
Unit price




Session date: May 23, 2023

Identifying endpoints that meet requirements for patient centricity, applicability given the known or likely mechanisms of the therapeutic intervention and achievability within the constraints of therapeutic trials is key to the design of therapeutic trials for patients with ILD.

• More fully appreciate the need for patient-centric outcomes in trials of therapies for patients with ILD
• Consider the use of specific, supplemental oxygen-related outcomes in their studies and trials
• Implement patient-centric outcomes that assess how patients with ILD feel and function in their daily lives

Jeffrey Swigris, DO, MS
Meena Kalluri, MD
Jeffrey Swigris, DO, MS
Kerri Aronson, MD, Msci
Ayodeji Adegunsoye, MD, MS
Kerri Johannson, MD, MPH, ATSF

Patient reported outcomes as endpoints in trial
Supplemental Oxygen Needs as a Trial Endpoint
Improving Home Spirometry to Make It a Viable Trial Endpoint
Data from Wearables as Trial Endpoints